Clinical Trial Update: Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL) [Phase 2]

View source ↗

Summary

This Phase 2 trial is evaluating pirtobrutinib in combination with rituximab for untreated marginal zone lymphoma and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Marginal Zone Lymphoma

Drugs mentioned

• Pirtobrutinib (pirtobrutinib)
• Rituximab (rituximab)

Snippet

Sponsor: University of Utah | Conditions: Marginal Zone Lymphoma | Phase 2 | Status: RECRUITING